Cargando…

1243. Eravacycline in Bacteremia: A Case Series

BACKGROUND: Eravacycline (ERV) is FDA-approved for the treatment of complicated intra-abdominal infections, but there is limited experience for non-FDA approved indications. METHODS: We present five cases that utilized ERV for treatment of bacteremia. RESULTS: Patient 1 in septic shock (SS) started...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrade, Justin A, Kosalka, Robert, Truong, James, Rosenberg, Joshua R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644661/ http://dx.doi.org/10.1093/ofid/ofab466.1435

Ejemplares similares

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
por: Carr, Amy, et al.
Publicado: (2020)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

1243. Hepatitis D Virus and Hepatitis B Virus Epidemiology in Utah
por: Hesterman, Matthew, et al.
Publicado: (2022)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

1978. Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection
por: Lawrence, Kenneth, et al.
Publicado: (2018)

P1243: FUNCTIONAL PRECISION ONCOLOGY FOR FOLLICULAR LYMPHOMA WITH PATIENT-DERIVED XENOGRAFT IN AVIAN EMBRYOS.
por: Zala, Manon, et al.
Publicado: (2023)

1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections
por: Smith, Bradley, et al.
Publicado: (2018)

1243. Semi-Quantitative Benefit-Risk Assessment for a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals 2 Years of Age and Older
por: Neveu, David, et al.
Publicado: (2020)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

203. Gardnerella vaginalis Bacteremia in Male Patients: A Case Series and Review of the Literature
por: Akamine, Christine, et al.
Publicado: (2021)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

261. A Single-Center Case Series of Methicillin-Resistant S. aureus Bacteremia with Elevated Minimal Inhibitory Concentrations to Vancomycin
por: Mills, Alexandra, et al.
Publicado: (2020)

399. Risk Factors for Mortality in COVID-19 Patients in a Community Teaching Hospital
por: Andrade, Justin A, et al.
Publicado: (2020)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

1243. Continuous vs. Intermittent Intraoperative Infusion of Cefazolin on Surgical Site Infections (SSIs) and Acute Kidney Injury in Patients Undergoing Cardiac Procedures
por: Tichy, Michael, et al.
Publicado: (2019)

1243. Acceptable susceptibility thresholds reported in hospital antibiograms for Gram-negative rod infections: a survey and contingent valuation study of infectious diseases providers
por: Hasegawa, Shinya, et al.
Publicado: (2023)

190. Outcomes of Early Ceftaroline-based Combination Therapy for Methicillin-resistant Staphylococcus aureus Bacteremia
por: Dolan, Mackenzie, et al.
Publicado: (2021)

189. A Case Series of Elizabethkingia meningosepticum Bacteremia in the Cancer Population
por: Hyun Lee, Dae, et al.
Publicado: (2019)

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
por: Alosaimy, Sara, et al.
Publicado: (2022)

Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With Mycobacterium Abscessus Infections and Review of Literature
por: Rausch, Ethan, et al.
Publicado: (2022)

1033. Thinking Outside the Bowel: Clostridium difficile Bacteremia Case Series
por: Pettigrew, Adam, et al.
Publicado: (2018)

P1243: RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL
por: Zhou, D., et al.
Publicado: (2022)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
por: Sauvonnet, Veronique, et al.
Publicado: (2019)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

195. Duration of Therapy for Streptococcal Bacteremia
por: Boulos, John M, et al.
Publicado: (2021)

253. Is Echocardiogram always indicated in Bacteremia?
por: Grinberg, Sagy, et al.
Publicado: (2020)

304. Predictors of mortality in carbapenem-resistant Enterobacteriales bacteremia
por: Hovan, Michael R, et al.
Publicado: (2020)

270. Clinical Outcomes of Ceftriaxone versus Penicillin G for Complicated Viridans Group Streptococci Bacteremia
por: Wo, Stephanie, et al.
Publicado: (2020)

2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2019)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

Correction to: Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With Mycobacterium Abscessus Infections and Review of Literature
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nhb5vake5qfgvtlks3bb9vlbte